Table 1.
Patient background and treatment history
| Characteristics | Analysis set (n = 205) |
|---|---|
| Age at index date, years | |
| Mean ± SD | 76.2 ± 7.2 |
| < 75, n (%) | 84 (41.0) |
| ≥ 75, n (%) | 121 (59.0) |
| Baseline body weight, kg, mean ± SDa | 62.3 ± 10.1 |
| Baseline BMI, mean ± SDb | 23.2 ± 3.2 |
| Gleason score at prostate cancer diagnosis, n (%) | |
| < 8 | 59 (28.8) |
| ≥ 8 | 123 (60.0) |
| Unknown | 23 (11.2) |
| Baseline PSA, ng/mLc | |
| Mean ± SD | 19.6 ± 93.1 |
| Median (range) | 6.3 (0–1306.1) |
| Baseline PSA doubling time, months | |
| Mean ± SD | 6 ± 21 |
| ≤ 10, n (%) | 180 (87.8) |
| > 10, n (%) | 21 (10.2) |
| Not measurable, n (%) | 4 (2.0) |
| Comorbidities (except prostate cancer) at initiation of enzalutamide, n (%) | |
| No | 44 (21.5) |
| Yes | 140 (68.3) |
| Unknown | 21 (10.2) |
| Prior curative therapy, n (%) | |
| Yes | 115 (56.1) |
| Surgery | 42 (20.5) |
| Radiotherapy | 57 (27.8) |
| Both | 16 (7.8) |
| No | 89 (43.4) |
| Unknown | 1 (0.5) |
| Median (range) time from diagnosis of prostate cancer to initiation of enzalutamide, monthsd | 70 (4–244) |
| Median (range) time from initiation of ADT to initiation of enzalutamide, monthse | 56 (3–227) |
| Initial daily dose of enzalutamide, n (%)f | |
| 40–80 mg | 24 (11.7) |
| 120 mg | 25 (12.2) |
| 160 mg | 156 (76.1) |
ADT androgen deprivation therapy; BMI body mass index; PSA prostate-specific antigen; SD standard deviation
aUnknown: n = 44 (21.5%)
bUnknown: n = 47 (22.9%)
cBaseline PSA defined as PSA measured within 3 weeks prior to the index date
dUnknown: n = 10 (4.9%)
eUnknown: n = 7 (3.4%)
fThe standard daily dose of enzalutamide is 160 mg; however, in this study, data were collected regardless of actual dose